Efficacy and Safety of Doloxetine in the Treatment of Subacute Herpes Zoster Neuralgia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900027181

Enrollment

Unknown

Registered

2019-11-03

Start date

2015-03-01

Completion date

Unknown

Last updated

2019-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subacute Herpes Zoster Neuralgia

Interventions

Experimental group:duloxetine with Oral administration of gabapentin, pregabalin and Mecobalamin

Control group:Oral administration of gabapentin, pregabalin and Mecobalamin

Eligibility

Sex/Gender

All

Age

61 Years to 83 Years

Inclusion criteria

Inclusion criteria: 1. Disease course lasted from January to March; 2. The lesion involvement range was T2-L5 spinal nerve distribution area; 2. All patients were rated with pain visual simulation scale(VAS), VAS >=5;

Exclusion criteria

Exclusion criteria: Exclusion criteria: with inability to match scores, or local infections, coagulation disorders, and severe heart, liver, and kidney diseases.

Design outcomes

Primary

Measure	Time frame
Pain;	—

Secondary

Measure	Time frame
SF-MPQ score, depression and anxiety self rating scale score;	—

Contacts

Public ContactYi Tang

Fujian Provincial Geriatric Hospital

915268985@qq.com+86 18965028928

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026